Clevidipine is an ultra-short-acting, arterial-selective dihydropyridine calcium channel blocker administered intravenously for acute blood pressure management in perioperative and intensive-care settings, metabolised rapidly by blood and tissue esterases. Simson Pharma's Clevidipine reference standard and impurities support the precise potency control required of this critical-care antihypertensive.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Clevidipine Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.